FeesSafety
Pluang+

Harbor Mid Cap Core ETF returns 12.99% in Q2, slightly underperforming Russell Midcap Index

Market News
17 Sep 2026
Seeking Alpha
View Source
Neutral
Harbor Mid Cap Core ETF returns 12.99% in Q2, slightly underperforming Russell Midcap Index

In the second quarter, the Harbor Mid Cap Core ETF (EPMB) posted a 12.99% return, slightly below its benchmark, the Russell Midcap® Index, which gained 13.83%. The ETF's underperformance was mainly due to lagging behind in the Information Technology sector, where a narrower group of high-growth stocks led the benchmark's gains. However, strong stock selection in Industrials, Health Care, and Consumer Staples helped support relative performance. The fund follows a fundamental investment approach focused on mid-cap stocks and is managed by Paul E. Viera with subadvisor EARNEST Partners LLC.

The Harbor Mid Cap Core ETF Q2 2026 Commentary provides context for mid-cap investment performance. For readers following US stocks on Pluang, here is the market snapshot as of Sep 17, 2026 19:44 WIB: out of 150 priced US stocks, 129 rose and 19 fell today. Among notable movers, Gold Fields Limited (GFI) rose 4.08% to USD 43.67 with a typical hold time of 48 days and a Pluang order activity of 59% Sell / 41% Buy, Caterpillar Inc (CAT) increased 4.00% to USD 814.01 with a longer hold time of 95 days and a 32% Sell / 68% Buy order split, while Lucid Group Inc (LCID) gained 3.96% to USD 4.20, showing the shortest hold time of 44 days and a full 100% Buy order activity.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
46 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
46 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
2 hours ago
Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Joseph Lubin, co-founder of Ethereum, predicts that artificial intelligence (AI) and cryptocurrency will merge on the Ethereum blockchain to create a system where automated tasks are commissioned, completed, and paid for with trust guaranteed by bloc...

Protocol Fundamentals
Bullish
4 hours ago
Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin's price dropped to around $80,494, down 1.26%, alongside a 14.11% decline in trading volume, indicating weaker market participation. Despite increased network activity and a slight rise in Bitcoin's market dominance, sentiment remained neutra...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App